이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Henagliflozin on Myocardial Fibrosis in Obese Patients (LY2026-317-C)

2026년 11월 14일 업데이트: Jing Ma

Effect of Henagliflozin on Myocardial Fibrosis in Obese Patients: A Prospective, Randomized, Controlled Study.

This study evaluates the anti-fibrotic efficacy and safety of henagliflozin versus metformin in non-diabetic obese patients with subclinical myocardial fibrosis, explores whether the benefit is mediated by metabolic improvement or direct myocardial protection, and aims to provide high-level evidence for early pharmacological intervention.

연구 개요

상태

아직 모집하지 않음

정황

개입 / 치료

상세 설명

This study will be based on an established specialized cohort of non-diabetic patients with simple obesity and a multi-omics database. By integrating clinical data with multidimensional information including genomics, metabolomics, and proteomics, patients at high risk of myocardial fibrosis will be identified. After myocardial fibrotic changes are further confirmed by CMR, eligible participants will be randomly assigned to the control group (metformin) or the intervention group (henagliflozin). The treatment period will be 24 weeks, followed by a 24-week safety follow-up period. The difference in the change in the degree of myocardial fibrosis before and after treatment between the two groups will be compared to determine the efficacy of henagliflozin in counteracting myocardial fibrosis in the non-diabetic obese population. This project aims to provide high-level evidence-based medical evidence for targeted pharmacological intervention of obesity-related early cardiac damage, with the goal of improving the long-term prognosis of this population.

연구 유형

중재적

등록 (추정된)

100

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  1. BMI ≥ 28 kg/m², or waist circumference ≥ 90 cm in men or ≥ 85 cm in women, or body fat percentage ≥ 25% in men or ≥ 30% in women;
  2. Adults aged 18 to 65 years;
  3. ECV greater than 30%;
  4. No participation in other clinical trials within the past three months.

Exclusion Criteria:

  1. Diagnosed with diabetes mellitus or prediabetes;
  2. History of coronary artery disease (coronary stenosis > 50% on coronary angiography or coronary computed tomography), history of myocardial infarction, history of coronary artery bypass grafting or percutaneous coronary intervention; non-ischemic cardiovascular diseases such as idiopathic cardiomyopathy, valvular disease, congenital heart disease, or cor pulmonale; arrhythmia or bundle branch block on electrocardiogram; implantation of a cardiac pacemaker or defibrillator;
  3. Uncontrolled hypertension: systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 100 mmHg during the screening visit (mean of three blood pressure measurements in the supine position);
  4. Symptomatic hypotension and/or systolic blood pressure < 90 mmHg at V1 or V2, or patients judged by the clinician to have hypovolemia;
  5. Use within 3 months of: 1) medications that may affect body weight or glucose metabolism, including systemic glucocorticoids (excluding topical, ophthalmic, nasal spray, or inhaled preparations; excluding low-dose or overnight dexamethasone suppression test use), growth hormone, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, tricyclic/tetracyclic antipsychotic drugs, other psychiatric medications or sedatives (e.g., imipramine, amitriptyline, mirtazapine, paroxetine, phenelzine, chlorpromazine, thioridazine, clozapine, olanzapine, valproic acid, valproic acid derivatives, lithium salts), etc.; 2) traditional Chinese medicines, Chinese patent medicines, herbal medicines, health supplements, meal replacements, etc., with weight-loss or glucose-lowering effects; 3) use of or current use of the following weight-loss drugs or drugs containing the following ingredients, such as: sibutramine hydrochloride, orlistat, phentermine, phenylpropanolamine, clobenzorex, fenfluramine, amfepramone, lorcaserin, phentermine/topiramate combination, naltrexone/bupropion combination, etc.; 4) use of glucose-lowering drugs, such as metformin, α-glucosidase inhibitors, sulfonylureas, dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium-glucose cotransporter-2 (SGLT2) inhibitors, thiazolidinediones (TZDs), insulin, etc.;
  6. Other endocrine and metabolic diseases such as hyperthyroidism, hypothyroidism, acromegaly, diabetes insipidus, or Cushing's syndrome;
  7. Concurrent malignant tumors;
  8. Severe liver disease (Child-Pugh class C) or liver enzymes (ALT/AST) > 3 times the upper limit of normal;
  9. Estimated glomerular filtration rate (eGFR) < 45 mL/min/1.73 m²;
  10. Cognitive impairment, or concomitant infectious or autoimmune diseases;
  11. History of recurrent urinary or reproductive tract infections;
  12. Patients who refuse henagliflozin or metformin treatment, or who are allergic to henagliflozin, metformin, or their excipients; those with incomplete questionnaires or incomplete data;
  13. Pregnant or breastfeeding women.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: 개입 그룹

Oral henagliflozin 10 mg once daily for 24 weeks, administered at a fixed dose without adjustment. Used in non-diabetic obese patients with subclinical myocardial fibrosis as an off-label investigational treatment.

활성 비교기: Control Group

oral metformin tablets 2000 mg/day; or the maximum tolerated dose (≥1000 mg/day).

Oral metformin titrated to 2000 mg/day (1000 mg twice daily), or the maximum tolerated dose (≥1000 mg/day), for 24 weeks. Dose titration: 500 mg twice daily for weeks 1-2, then 1000 mg twice daily from week 3 if tolerated.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Change from Baseline in Myocardial Extracellular Volume (ECV) Fraction at 24 Weeks
기간: Baseline to Week 24

Change from baseline in myocardial extracellular volume (ECV) fraction, as measured by cardiac magnetic resonance (CMR) T1 mapping pre- and post-contrast. ECV is calculated from pre- and post-contrast T1 relaxation times and the patient's hematocrit. The between-group difference in ΔECV (Henagliflozin vs. Metformin) will be compared; continuous data will be summarized as mean ± SD and analyzed using mixed-effects models.

Baseline to Week 24

2차 결과 측정

결과 측정
기간
Change from Baseline in Epicardial Adipose Tissue (EAT) Volume at 24 Weeks
기간: Baseline to Week 24
Baseline to Week 24
Change from Baseline in Left Ventricular Ejection Fraction (LVEF) at 24 Weeks
기간: Baseline to Week 24
Baseline to Week 24
Change from Baseline in Cardiac Output at 24 Weeks
기간: Baseline to Week 24
Baseline to Week 24
Change from Baseline in Heart Rate at 24 Weeks
기간: Baseline to Week 24
Baseline to Week 24
Change from Baseline in Peak Filling Rate at 24 Weeks
기간: Baseline to Week 24
Baseline to Week 24
Change from Baseline in Stroke Volume Index (BSA-corrected) at 24 Weeks
기간: Baseline to Week 24
Baseline to Week 24
Change from Baseline in End-Systolic Volume Index (BSA-corrected) at 24 Weeks
기간: Baseline to Week 24
Baseline to Week 24
Change from Baseline in End-Diastolic Volume Index (BSA-corrected) at 24 Weeks
기간: Baseline to Week 24
Baseline to Week 24
Change from Baseline in Left Ventricular Mass Index (BSA-corrected) at 24 Weeks
기간: Baseline to Week 24
Baseline to Week 24
Change from Baseline in Early-to-Late Filling Ratio (E/A) at 24 Weeks
기간: Baseline to Week 24
Baseline to Week 24
Change from Baseline in LV Mass to End-Diastolic Volume Ratio (MVR) at 24 Weeks
기간: Baseline to Week 24
Baseline to Week 24
Change from Baseline in Cardiac Index at 24 Weeks
기간: Baseline to Week 24
Baseline to Week 24
Change from Baseline in Body Weight at 24 Weeks
기간: Baseline to Week 24
Baseline to Week 24
Change from Baseline in Body Mass Index (BMI) at 24 Weeks
기간: Baseline to Week 24
Baseline to Week 24
Change from Baseline in Systolic Blood Pressure at 24 Weeks
기간: Baseline to Week 24
Baseline to Week 24
Change from Baseline in Diastolic Blood Pressure at 24 Weeks
기간: Baseline to Week 24
Baseline to Week 24
Change from Baseline in Glycated Hemoglobin (HbA1c) at 24 Weeks
기간: Baseline to Week 24
Baseline to Week 24
Change from Baseline in Fasting Plasma Glucose at 24 Weeks
기간: Baseline to Week 24
Baseline to Week 24
Change from Baseline in HOMA-IR (Insulin Resistance Index) at 24 Weeks
기간: Baseline to Week 24
Baseline to Week 24
Change from Baseline in Total Cholesterol at 24 Weeks
기간: Baseline to Week 24
Baseline to Week 24
Change from Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at 24 Weeks
기간: Baseline to Week 24
Baseline to Week 24
Change from Baseline in High-Density Lipoprotein Cholesterol (HDL-C) at 24 Weeks
기간: Baseline to Week 24
Baseline to Week 24
Change from Baseline in Triglycerides at 24 Weeks
기간: Baseline to Week 24
Baseline to Week 24
Change from Baseline in High-sensitivity CRP (hsCRP) at 24 Weeks
기간: Baseline to Week 24
Baseline to Week 24

기타 결과 측정

결과 측정
기간
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
기간: Up to 48 Weeks
Up to 48 Weeks
Number of Participants With Genitourinary Tract Infections
기간: Up to 48 Weeks
Up to 48 Weeks
Number of Participants With Gastrointestinal Adverse Events
기간: Up to 48 Weeks
Up to 48 Weeks
Number of Participants With Ketoacidosis
기간: Up to 48 Weeks
Up to 48 Weeks
Number of Participants With Serious Adverse Events (SAEs)
기간: Up to 48 Weeks
Up to 48 Weeks

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

수사관

  • 수석 연구원: Jing Ma, Department of Endocrinology, Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2026년 12월 1일

기본 완료 (추정된)

2028년 10월 1일

연구 완료 (추정된)

2028년 10월 1일

연구 등록 날짜

최초 제출

2026년 11월 1일

QC 기준을 충족하는 최초 제출

2026년 11월 14일

처음 게시됨 (실제)

2026년 11월 19일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 19일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 14일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • LY2026-317-C

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .